Phathom Pharmaceuticals Aktie
WKN DE: A2PT0F / ISIN: US71722W1071
01.04.2025 14:33:43
|
Phathom Pharmaceuticals Appoints Steven Basta To Succeed Terrie Curran As President And CEO
(RTTNews) - Biopharmaceutical company Phathom Pharmaceuticals, Inc. (PHAT) announced that Steven Basta has been appointed President and Chief Executive Officer and a member of the Board of Directors, effective immediately.
Basta succeeds Terrie Curran, who is stepping down as President and CEO and as a member of the Board of Directors for personal reasons.
Basta has more than 25 years of leadership experience in the biopharmaceutical and medical device industry. He served as CEO of SaNOtize, a company that develops and commercializes anti-infective therapies since 2023.
Prior to this role, he served as CEO of Mahana Therapeutics, a prescription digital therapeutic company. He previously served as CEO of Menlo Therapeutics (now VYNE Therapeutics), AlterG, BioForm Medical and its successor Merz Aesthetics.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Phathom Pharmaceuticals Inc Registered Shsmehr Nachrichten
06.08.25 |
Ausblick: Phathom Pharmaceuticals informiert über die jüngsten Quartalsergebnisse (finanzen.net) | |
30.04.25 |
Ausblick: Phathom Pharmaceuticals präsentiert Bilanzzahlen zum jüngsten Jahresviertel (finanzen.net) |
Analysen zu Phathom Pharmaceuticals Inc Registered Shsmehr Analysen
Aktien in diesem Artikel
Phathom Pharmaceuticals Inc Registered Shs | 12,21 | 3,30% |
|